Brentuximab Vedotin ermöglicht eine effektive Konsolidierungstherapie bei Risiko-HL-Patienten Lymphoma Share: Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me Forgot password? Click here
Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me